Corrigendum to "Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study" [Park. Relat. Disord. 28 (2016) 49-55]
Parkinsonism Relat Disord
.
2017 May:38:108.
doi: 10.1016/j.parkreldis.2017.02.030.
Epub 2017 Feb 24.
Authors
Zhen-Xin Zhang
1
,
Hui-Fang Shang
2
,
Xingyue Hu
3
,
Shengdi Chen
4
,
Zhongxin Zhao
5
,
Xinlu Du
6
,
Erwin Surmann
7
,
Lars Bauer
8
,
Mahnaz Asgharnejad
9
Affiliations
1
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
2
West China Hospital, Sichuan University, Chengdu, Sichuan, China.
3
Sir Run Run Shaw Hospital affiliated to School of Medicine, Zhejiang University, Zhejiang, China.
4
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
5
Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China.
6
UCB Pharma, Shanghai, China.
7
UCB Pharma, Monheim am Rhein, Germany.
8
UCB Pharma, Monheim am Rhein, Germany. Electronic address:
[email protected]
.
9
UCB Pharma, Raleigh, NC, USA.
PMID:
28258926
DOI:
10.1016/j.parkreldis.2017.02.030
No abstract available
Publication types
Comment